000725:SZSEHyundai Engineering & Construction Co.,Ltd. Analysis
Data as of 2026-06-01 - not real-time
CN¥5.36
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
BOE Technology is trading at CNY 5.36, comfortably above its 20‑day (CNY 4.66), 50‑day (CNY 4.29) and 200‑day (CNY 4.20) simple moving averages, indicating a strong bullish bias. The RSI sits at 65.4 and the MACD line is positive (0.35) with a bullish histogram, while volume is on an increasing trend, all of which support short‑term upside potential. Valuation appears reasonable: the trailing PE of 31.5 is well below the industry average PE of 42.7, and the price‑to‑sales ratio is under 1 (0.97), suggesting the stock is not overly expensive relative to peers. The beta of 0.31 points to low market‑wide volatility, and the Fear‑Greed Index at 93 (Extreme Greed) reflects strong investor sentiment.
Fundamentally, the company faces challenges: revenue growth is modest at 0.8 %, margins are thin (gross 13.7 %, operating 5.5 %, profit 2.9 %), and the debt‑to‑equity ratio is high at 68.9 %, though cash balances are substantial. Return metrics are weak (ROE 2.3 %, ROA 0.7 %) and free cash flow is limited (CNY 0.85 bn). The dividend yield of 0.98 % with a payout ratio of 29 % appears sustainable, providing a modest income cushion for investors.
Fundamentally, the company faces challenges: revenue growth is modest at 0.8 %, margins are thin (gross 13.7 %, operating 5.5 %, profit 2.9 %), and the debt‑to‑equity ratio is high at 68.9 %, though cash balances are substantial. Return metrics are weak (ROE 2.3 %, ROA 0.7 %) and free cash flow is limited (CNY 0.85 bn). The dividend yield of 0.98 % with a payout ratio of 29 % appears sustainable, providing a modest income cushion for investors.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and RSI indicating momentum
- Price above all major SMAs supporting trend
- Increasing trading volume confirming participation
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Valuation near fair value with modest upside
- High debt-to-equity ratio limiting financial flexibility
- Limited earnings growth and thin profit margins
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Low ROE and ROA suggest weak long‑term profitability
- Diversified product portfolio (IoT, MLED, smart medicine) provides strategic upside
- Sustainable dividend offering a defensive income component
Key Metrics & Analysis
Financial Health
Revenue Growth0.80%
Profit Margin2.90%
P/E Ratio31.5
ROE2.30%
ROA0.71%
Debt/Equity68.95
P/B Ratio1.5
Op. Cash FlowCN¥47.4B
Free Cash FlowCN¥852.2M
Industry P/E42.7
Technical Analysis
TrendBullish
RSI65.4
SupportCN¥4.08
ResistanceCN¥6.09
MA 20CN¥4.66
MA 50CN¥4.29
MA 200CN¥4.20
MACDBullish
VolumeIncreasing
Fear & Greed Index93.04
Valuation
Target PriceCN¥4.92
Upside/Downside-8.25%
GradeFair
TypeBlend
Dividend Yield0.98%
Risk Assessment
Beta0.31
Volatility61.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.